[HTML][HTML] T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
Journal for immunotherapy of cancer, 2023•ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors have revolutionized cancer treatment. However,
they are associated with a unique spectrum of side effects, called immune-related adverse
events (irAEs), which can cause significant morbidity and quickly progress to severe or life-
threatening events if not treated promptly. Identifying predictive biomarkers for irAEs before
immunotherapy initiation is therefore a critical area of research. Polymorphisms within the T-
cell receptor beta (TCRB) variable (TRBV) gene have been implicated in autoimmune …
they are associated with a unique spectrum of side effects, called immune-related adverse
events (irAEs), which can cause significant morbidity and quickly progress to severe or life-
threatening events if not treated promptly. Identifying predictive biomarkers for irAEs before
immunotherapy initiation is therefore a critical area of research. Polymorphisms within the T-
cell receptor beta (TCRB) variable (TRBV) gene have been implicated in autoimmune …
Abstract
Background
Immune checkpoint inhibitors have revolutionized cancer treatment. However, they are associated with a unique spectrum of side effects, called immune-related adverse events (irAEs), which can cause significant morbidity and quickly progress to severe or life-threatening events if not treated promptly. Identifying predictive biomarkers for irAEs before immunotherapy initiation is therefore a critical area of research. Polymorphisms within the T-cell receptor beta (TCRB) variable (TRBV) gene have been implicated in autoimmune disease and may be mechanistically linked to irAEs. However, the repetitive nature of the TCRB locus and incomplete genome assembly has hampered the evaluation of TRBV polymorphisms in the past.
ncbi.nlm.nih.gov